Results 231 to 240 of about 70,073 (274)

Sequential Therapies in Castration-Resistant Prostate Cancer

Future Oncology, 2014
153 ISSN 1479-6694 10.2217/FON.13.243 © 2014 Future Medicine Ltd Future Oncol. (2014) 10(2), 153–155 An unprecedented large number of agents capable of prolonging survival is presently available for patients with castrationresistant prostate cancer (CRPC) [1,2].
Carlo, Buonerba, Giuseppe, Di Lorenzo
openaire   +2 more sources

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

The Lancet, 2010
J. D. Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels, I. Kocák, G. Gravis, I. Bodrogi, Mary J Mackenzie, L. Shen, M. Roessner, Sunil Gupta, A. O. Sartor   +12 more
semanticscholar   +1 more source

New Therapies for Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2010
On April 29, 2010, the Food and Drug Administration (FDA) approved a new immunotherapy, sipuleucel-T, for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer. Traditionally, immune-based therapies have been categorized according to whether the agent has direct antitumor effects (so-called passive ...
openaire   +2 more sources

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

European Urology, 2017
P. Cornford, J. Bellmunt, M. Bolla, E. Briers, M. De Santis, T. Gross, A. Henry, S. Joniau, T. Lam, M. Mason, H. G. van der Poel, T. H. van der Kwast, O. Rouvière, T. Wiegel, N. Mottet   +14 more
semanticscholar   +1 more source

[Castration-resistant prostate cancer (CRPC)].

Der Urologe. Ausg. A, 2014
In merely a short period of time the comprehension of castration-resistant prostate cancer has evolved. It is now possible to clearly outline the exact definition and variance of the disease pattern. A wealth of new effective agents can be applied to extend the patient's life span and improve the quality of life.
W, Loidl, F, Luger, A, Roosen
openaire   +1 more source

[Castration resistant prostate cancer 2015].

Aktuelle Urologie, 2016
Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant
A S, Merseburger, A, Böker, M A, Kuczyk, C-A, von Klot   +3 more
openaire   +1 more source

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

The Lancet Oncology, 2021
J. D. de Bono, N. Mehra, G. Scagliotti, E. Castro, T. Dorff, A. Stirling, A. Stenzl, M. Fleming, C. Higano, F. Saad, C. Buttigliero, I. V. van Oort, A. Laird, M. Mata, Hsiang-Chun Chen, C. Healy, A. Czibere, K. Fizazi   +17 more
semanticscholar   +1 more source

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ca-A Cancer Journal for Clinicians, 2021
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel   +2 more
exaly  

Cancer statistics, 2023

Ca-A Cancer Journal for Clinicians, 2023
Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle   +2 more
exaly  

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

The Lancet Oncology, 2012
K. Fizazi, H. Scher, A. Molina, C. Logothetis, K. Chi, Robert J. Jones, J. Staffurth, S. North, N. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. Goodman, C. Sternberg, J. H. Li, T. Kheoh, C. Haqq, J. D. de Bono   +17 more
semanticscholar   +1 more source